Skip to main content
. 2021 Aug 17;22:543. doi: 10.1186/s13063-021-05520-1

Fig. 1.

Fig. 1

Study design. Arrows indicate the application time points of secukinumab and placebo; stars indicate the time points at which imaging (ultrasound and/or magnetic resonance angiography) is performed. BSL, baseline; mg, milligram; s.c., subcutaneous; R, randomization (randomization occurs after the 6-week screening period at baseline); n, number